PNC Financial Services Group’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRS
BCM
DTC
RCM
VC
VCM
FLSM
RSCM
DC
PNC Financial Services Group's ACRS Position: Q1 2026 in Review
PNC Financial Services Group held its Aclaris Therapeutics (ACRS) position steady in Q1 2026 at 2,070 shares worth $7.76K. The position accounts for ﹤0.01% of the portfolio, ranked #4063.
PNC Financial Services Group first reported a position in ACRS in Q4 2016 and has held it in 19 quarters since. The position peaked at $250K in Q2 2017. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.
- PNC Financial Services Group held 2,070 shares of Aclaris Therapeutics worth $7.76K as of Q1 2026.
- PNC Financial Services Group left its Aclaris Therapeutics share count unchanged in Q1 2026.
- Aclaris Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #4063 holding.
- PNC Financial Services Group first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 19 quarters since.
- PNC Financial Services Group's Aclaris Therapeutics position peaked at $250K in Q2 2017.
- 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.
Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.